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SUMMARY
The biological availability of chloramphenicol from dif-
ferent commercial preparations was investigated. Methods
used to evaluate the in vitro release were disintegration,
de-aggregation and dissolution tests and particle size
measurement. Considerable differences between the rate
of release of the antibiotic from the different capsule
preparations were detected. These differences can be at-
tributed to the formulation used during the preparation
of the different products. The absorption characteristics
of chloramphenicol from 3 brands of chloramphenicol
capsules and 3 chloramphenicol powder samples from
different sources were tested on 6 healthy male subjects
in a cross-over trial. Each subject received 500 mg as a
single oral dose at intervals of one week. Significant
differences between the average amount of chlorampheni-
col excreted in the urine from the different preparations
were noted 1· 2 hours after administration of the dose.
The experimental results were used to compute the ab-
sorption rate of the antibiotic from different preparations.
The differences observed in the in vitro release were con-
firmed by the in vivo results. The differences between the
release of the antibiotic from the different capsule prepa-
rations could be ascribed to the method of formulation
of the antibiotic which is poorly soluble in water.
s. Afr. Med. l., 47, 94 (1973).
The necessity to assure the biological availability of
drugs from drug products has been emphasized to a
great extent in the past decade. Several examples of
drug products which had little or no th~rapeutic effect
have been reported.'·' The hazards of therapeutic non-
equivalency of drug products are obvious and it is,
therefore, necessary to emphasize the need for caution
in assuming that absorption characteristics are the same
for a drug from different preparations.
Using dogs as experimental animals the in vivo abs-
orption of chloramphenicol from capsules, each
originating from 4 different manufacturers, has been
studied. No significant difference in serum concentrations
and rate of elimination of the drug from the blood was
noted.' Glazko et al.' and Aguiar et al.s studied the in
vitro dissolution and de-aggregation as well as the in
vivo absorption of chloramphenicol from 4 different
chloramphenicol preparations in human adults. A distinct
variation in the intestinal absorption pattern of chlor-
amphenicol from the different preparations was noted,
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and these differences can be correlated with the differences
in dissolution and de-aggregation rate of the different
preparations.
Martin et al.' concluded from their experiments with
3 different chloramphenicol capsule products that the
rate of absorption for 1 product was considerably faster
than with the other 2 products. When the contents of
these 2 products were recrystalized, no difference was
observed. It was, therefore, concluded that the particle
size of the drug influenced the dissolution and absorption
rate of the drug. The absorption of chloramphenicol
from two different preparations in 20 male volunteers
receiving each a dose of 1,0 g chloramphenicol every
6 hours for 48 hours, was studied. I. Significantly higher
blood concentrations of chloramphenicol from one pre·
paration were observed during the first hour; but 18
hours after the first administration the serum concen-
tration from the other preparation was greater. After
reformulation of the one preparation, it produced similar
blood concentrations of chloramphenicol to the other
preparation.
In an extensive comparison between 5 different cap-
sules, 4 different tablets and 5 different suspensions, it
was found that there were significant differences in the
rate of absorption of chloramphenicol from the gastro-
intestinal tract. In all the cases there was a close
correlation between absorption rate and dissolution
rate." From the results in the quoted literature it is
apparent that the formulation of chloramphenicol into
a drug product plays a very important part in the
release characteristics of the drug from the particular
dosage form.
For this reason the bio-availability of chloramphenicol
from different capsules on the South African market
was studied. The use of certain in vitro methods are
suggested for quality control purposes so as to' predict
the in vivo absorption rate from commercially available
products.
EXPERIMENTAL METHODS
Assay of Chloramphenicol Capsules
Chemical method: The chloramphenicol content In
the different capsules was determined by the method
described in the British Pharmacopoeia (RP.) (1968).
Microbiological method: The microbiological assay
was done by using Bacillus subtilus as test organism.
The method used complied with the method of the
B.P. (1968).




The disintegration time of the different capsules was
determined according to the B.P. (1968) pecifications,
using a Manesty tablet disintegration test unit without
a disc. A capsule was placed in each of the 6 tubes
containing 250 cm' of simulated gastric fluid without
pepsin." Five, ten and fifteen minutes after tbe unit
was put into operation, 5 cm' aliquots of each tube
were withdawn, centrifuged at 2000 rpm for 2 minutes,
and 2 cm' of the supernatant was diluted appropriately
with simulated gastric fluid and assayed spectrophoto-
metrically at 278 nm. After the removal of a sample
the same amount of gastric fluid was replaced. The
disintegration time of each capsule was recorded. This
procedure was repeated for each of the capsule products.
De-aggregation Rate Determination
The method used was essentially the same as reported
by Aguiar et al." For each determination 1 litre simulated
gastric fluid without pepsin" and presaturated with
chloramphenicol at 37"C was added to a 2-litre beaker
placed in a constant-temperature bath set at 37 ± 0,5°C.
The solution was stirred at 100 rpm with a blade-stirrer
without creating a vortex. The solution circulated via
a plastic tube, with a 0,3 cm internal diameter, through
a flow cell located in a Beckman DBG spectrophotometer.
The flow rate of the medium through the cell was
determined and kept constant for each determination at
60 cm' per minute. Gastric fluid presaturated with
chloramphenicol at room temperature, was used as a
blank for the determinations. A Beckman recording unit
was connected to the spectrophotometer, set on the
linear registration position and adjusted to record 100%
light transmittance at 650 nm. After the medium was
allowed to reach the determined temperature, 2 capsules
were placed in the beaker. A stopwatch was started
simultaneously to check the time on the recorder. The
de-aggregation pattern for each capsule was recorded
for 60 minutes.
Dissolution Rate Determination
The apparatus used was essentially the same as the
one previously reported." One litre of simulated gastric
fluid without pepsin" was placed in a 2-litre beaker in
a constant-temperature bath at 37 ± 0,5°C and stirred
at 100 rpm. One capsule was placed in the capsule
holder and placed in position. A filter was connected to
a plastic tube to withdraw 2 cm' samples at predetermined
time intervals. The same volume of dissolution medium
was replaced via the filter after removal of each sample.
The samples were diluted appropriately with dissolution
medium and assayed spectrophotometrically at 278 nm.
Particle Size Determination
The particle size of the chloramphenicol in the
different samples was determined with a Zeiss Particle
9
Size Analyzer TGZ3." Microscopic slides were prepared
for each sample and recorded photographically. After
appropriate enlargement, the photographs were used to
determine the particle size distribution. The average
particle diameter was calculated according to the appro-
priate equation."
Absorption Rate Determination
Six healthy male volunteers were used in a cross-over
study testing chloramphenicol capsule A, B and C as well
as chloramphenicol powder sample A, Band C. The
subjects weighed 71 - 75 kg and were between 20 and 23
years of age. All of them had a good medical record
and had no hi5tory of renal dysfunction. Urine samples
were collected 24 hours before each medication to serve
as a blank. All subjects received a single oral dose
corresponding to 500 mg chloramphenicol of each product
at intervals of one week between each dose. Each
chloramphenicol capsule was administered eventually to
each of the 6 subjects, but each chloramphenicol powder
sample was administered to only 2 subjects. The subjects
received the dose together with a glass of water half
an hour before a light breakfast. Urine samples were
collected at 0,5; 1; 2; 3; 4; 6; 8; 12; 24; and 48 hours
after dosage. After measuring the volume of the samples,
it was kept at 4°C before analysis. The amount of
chloramphenicol in the urine was determined by a
colorimetic method basically the same as described by
Glazko et al., " and modified by the Food and Drug
Administration." A digital computer was used to calculate
the absorption rates and other pharmacokinetic parameters
for chloramphenicol from the cumulative amount of
chloramphenicol excreted in the urine. The following
pharmacokinetic model was used to describe the abs-
orption and excretion of chloramphenicol:
k, k:.,
A-lag ---i> B ---i> U
where A = amount drug in gastro-intestinal tract,
k, rate constant for absorption of drug from the
gastro-intestinal tract.
k, rate constant for elimination of drug into urine,
B amount of drug in body,
U amount of drugs in urine.










The results of both chemical and microbiological assays
of each capsule are given in Table 1. Only capsule B
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did not comply with the requirements of the B.P. (1968)
in that each chloramphenicol capsule should contain
between 92,4 and 107,5% of the label claim. However,
if the microbiological assay results are considered appli-
cable to the same limits, then capsules B, C and D do
not comply with these standards. It has been proved
that no known chemical assay method for chloramphenicol
is capable of determining the amount of active chlor-
amphenicol. lO,'" The only method of determining the
amount of active antibiotic is a microbiological assay.
By using the official chemical assay method, inactive
degradation products of chloramphenicol, such as those
present in capsule D, were assayed as active chloram-
phenicol and this is the reason why this capsule wrongly
complied with the standards, but failed to do so with
a microbiological assay.
TABLE I. ASSAY OF CHLORAMPHENICOL CAPSULES
capsules A, B, C, D, and E was 4,65 ± 0,3; 6,75 ± 2,1;
7,7 ± 1,8; 4,68 ± 0,3 and 6,55 ± 0,2 minutes, respectively.
Capsule A and D disintegrated faster than any of the
other capsules while capsule C had the slowest disin-
tegration rate. All the capsules disintegrated within the
15 minutes required by the B. P. (1968). The chloram-
phenicol in capsule E dissolved faster than any of the
other capsules while only approximately 50% of the
chloramphenicol in capsule B dissolved in 15 minutes.
No correlation existed between the disintegration time
and the amount of chloramphenicol dissolved. A true
indication of the dissolution rate of chloramphenicol from
a capsule was not possible by using the disintegration
apparatus. These results were comparable to those re-
ported elsewhere."
Determination of De-aggregation Rate





































In Fig. 2 the percentage transmission is plotted against
time. A higher percentage transmission is obtained with
a higher de-aggregation state. The de-aggregation rate
of each capsule can be evaluated from the slopes of
the curves, or it can be expressed by the de-aggregation
T 50% which in this case is the time required to reach
half of the de-aggregation state of the final value
obtained after 60 minutes for each capsule. For capsules
A, B, C, D and E the de-aggregation- T 50% was respec-
tively 2,0; 7,4; 11,0; 2,8 and 13,5 minutes. A correlation
existed between the disintegration time and de-aggregation-
T 50% for the capsules.
Disintegration Time
The results of the disintegration and dissolution tests





Fig. 1. Dissolution rate of chloramphenicol capsules as
determined with disintegration apparatus. Arrows indicate
disintegration time.
TINE (man)
Fig. 2. De-aggregation rate of chloramphenicol in different
capsules.
Dissolution Rate Studies
The results of the dissolution rate determinations are
given in Fig. 3. The rate of dissolution for chloramphe..
nicol from each capsule can be evaluated from the
slope of the curve or can be expressed as the dissolution-
T 50% which is the time required to dissolve half the
amount· (125 mg) of chloramphenicol in a capsule.
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Capsules A, B, C and D had a dissolution- T 50% of
2,4; 17,6; 33,0 and 3,6. respectively. Capsule E was
still an intact capsule after 90 minutes in the dissolution
beaker and only approximately 23 % chloramphenicol
dissolved during this period. A correlation existed both
between the disintegration time and de-aggregation and
dissolution rates for capsule A, B, C and D.
Particle Size Distribution
Fig. 4. Particle size distribution of chloramphenicol
samples.
The particle size distribution of the different chloram-
phenicol powders are plotted on semilogarithrnic paper
in Fig. 4. The calculated average particle diameter was
41,3 }-lm, 71,1; 93,4; 49,6 and 72,5 }-lm for chloramphenicol
powder samples A, B, C, D and E, respectively. The
particle size distribution of sample A and D was almost
similar.
In Vivo Determinations
The experimental results, the calculated excretion rate
and cumulative amount chloramphenicol excreted for
capsules A, B, and C are illustrated in Fig. 5.
From Fig. 5 it can be concluded that capsule A released
its contents faster than capsule B or C, if the lag time
is taken into account. In Table II the average amount
of chloramphenicol excreted after administering capsule
A, B, and C are given as well as the calculated parameters
for the different capsules. The only statistically significant
differences between the capsules, as expressed by the
amount excreted, were noticed I hour after ingestion of
the antibiotic. Capsule A proved to have the fastest
rate of absorption and this can be correlated with the
results of the in vitro tests.
...•..
...







Fig. 5. Computed curves and experimental data points
for urinary excretion of total chloramphenicol equivalents
of capsules A, Band C (dose 500 mg).
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TABLE 11. EXPERIMENTAL RESULTS AND CALCULATED PARAMETERS FiOR CHLORAMPHENICOL CAPSULES
Average cumulative amount excreted after 500 mg doses
Capsule A Capsule B Capsule C
Time (h) (mg) (mg) (mg)
0,5 1,9 -+- 3,7 0,8 -+- 0,9 1,5 -+- 2,8
1 "21,4 -+- 19,2 "4,9 -+- 4,8 "6,4 -+- 10,9
2 49,8 -+- 21,2 36,4 -+- 20,6 28,4 -+- 31,9
3 72,S -+- 34,1 69,3 -+- 23,1 36,6 -+- 39,5
4 93,3 -+- 33,3 106,0 -+- 45,2 85,8 -+- 48,8
6 156,8 -+- 75,7 166,8 -+- 39,3 136,4 :± 54,7
8 191,0 -+- 76,1 204,1 -+- 44,4 154,1 :± 64,8
12 267,4 -+- 129,5 265,5 -+- 65,7 221,8 -+- 83,2
24 303,3 -+- 134,6 330,9 -+- 117,1 _263,2 -+- 123,2
48 310,4 -+- 133,9 335,2 -+- 118,4 273,2 -+- 122,8
42,1% 67,04% 54,6%
Calculated parameters
t'/2 (h) 4,07 4,60 4,08
T max. (h) 2,99 2,51 3,06
C max. (mg) 38,98 35,05 27,00
La9. (h) 0,00 0,34 0,27
k J (h"') 0,58 0,83 0,53
k2 (h-') 0,17 0,15 0,17
• Significant differences between average amount excreted evaluated with Studen!"s e-test (P>O.05).
TABLE Ill. EXPERIMENTAL RESULTS AND CALCULATED PARAMETERS FOR CHLORAMPHENICOL POWDERS














































































.. Significant differences between average amount excreted evaluated with Student's i-test (P>O,05).
The results of the excretion of the different chloram-
phenicol powder samples are given in Fig. 6. From this
figure and the calculated parameters in Table III it is
obvious that chloramphenicol from powder sample A
was absorbed faster than from both Band C. Likewise,
this difference was only significant during the first hour
after administration. This could be correlated with the
average particle size of the different chloramphenicol
powder samples.





Fig. 6. Computed curves and experimental data points for
urinary excretion of total chloramphenicol equivalents of
powders A, Band C (dose SOO mg).
CONCLUSION
The formulation of chloramphenicol in the different
capsules had an influence on the biological availability
of the antibiotic. Particle size, apparent presence of a
dispersing or wetting agent and other adjuvants used
had an influence on the dissolution rate of chloramphe-
nicol from the capsules. The storage conditions of thc
capsules also had an influence on the release rate, since
it was brought to our attention that capsule E had been
stored in an open container for several months before
the tests were conducted. Moisture obviously had an
influence on the dissolution rate of this capsule." As the
in vitro results can be correlated with the in vivo results.
it seems obvious that in vitro tests can be used to test
the biological availability of chloramphenicol. The results
obtained in this study again emphasize the need for
efficient quality control methods during and after the
product is manufactured. Factors that could limit the
biological availability of a drug from a drug product
should be investigated thoroughly so that the optimum
biological availability can be achieved at any time.
This work was financed in part by a research grant from
the South African Council for Scientific and Industrial Re-
search.
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